BAFNA PHARMACEUTICALS
|
The Current P/E Ratio of BAFNA PHARMACEUTICALS is 32.98.
| Share Price | ₹134.5 | May 27,2026 |
| Market Cap | ₹318.8 Cr | |
| Earnings-TTM | ₹9.7 Cr | TTM-Standalone Results |
| Price/Earnings | 32.98x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of BAFNA PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹318.8 Cr] as on May 27,2026
(/) Earnings [ ₹9.7 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 32.98x ]
Thus, for BAFNA PHARMACEUTICALS , the investors are currently willing to pay 32.98 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BAFNA PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BAFNA PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of BAFNA PHARMACEUTICALS
PE Ratio Performance Analysis for BAFNA PHARMACEUTICALS
- BAFNA PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 39.60x.
- BAFNA PHARMACEUTICALS 's operated at median p/e ratio of 42.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BAFNA PHARMACEUTICALS 's p/e ratio peaked in Mar2022 at 57.59x.
- BAFNA PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 17.24x.
How does BAFNA PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| BAFNA PHARMACEUTICALS | 9.67 | 32.98 | 318.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 38.28 | 442,677.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 70.27 | 180,458.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 71.88 | 153,685.0 |
| CIPLA LTD | 3,869.79 | 29.60 | 114,562.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.57 | 110,095.0 |
| MANKIND PHARMA LTD | 1,926.41 | 51.89 | 99,957.1 |
| LUPIN LTD | 5,355.47 | 19.44 | 104,097.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 21.74 | 109,272.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 23.59 | 82,604.1 |
| LAURUS LABS LTD | 889.85 | 83.79 | 74,562.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BAFNA PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.44x |
| Max industry PE | 83.79x |
| Median industry PE | 32.98x |
| Average industry PE | 42.73x |
You may also like the below Video Courses